Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

Patent metadata

Field	Value
Publication number	US-10239934-B2
Application number	US-201815918343-A
Country	US
Kind code	B2
Filing date	Mar 12, 2018
Priority date	Mar 17, 2009
Publication date	Mar 26, 2019
Grant date	Mar 26, 2019

Abstract

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

First claim

What is claimed is:

1. A method of inhibiting HIV in a host comprising administering to the host a non-naturally occurring monoclonal anti-HIV antibody, designated 1496 C09 (PG9) or antigen binding portion thereof comprising (a) a light chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS: 45, 126 and 127 and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 7, 123 and 124.

2. A method of inhibiting HIV in a host comprising administering to the host a non-naturally occurring monoclonal anti-HIV antibody, designated 1443 C16 (PG16) or antigen binding portion thereof comprising (a) a light chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 41, 95, and 97 and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 6, 88 and 89.

3. A method of inhibiting HIV in a host comprising administering to the host a non-naturally occurring monoclonal anti-HIV PG9 antibody or antigen binding portion thereof comprising a light chain sequence of SEQ ID NO: 30 and a heavy chain sequence of SEQ ID NO: 28.

4. A method of inhibiting HIV in a host comprising administering to the host a non-naturally occurring monoclonal anti-HIV PG16 antibody or antigen binding portion thereof comprising a light chain sequence of SEQ ID NO: 14 and a heavy chain sequence of SEQ ID NO: 12.

5. The method of any one of claims 1 - 4 , wherein the antibody or antigen binding portion thereof is administered with a pharmaceutically acceptable carrier.

6. An expression vector that encodes and stably expresses in vivo an antibody comprising each of a light chain sequence of SEQ ID NO: 30 and a heavy chain sequence of SEQ ID NO: 28.

7. An expression vector that encodes and stably expresses in vivo an antibody comprising each of a light chain sequence of SEQ ID NO: 14 and a heavy chain sequence of SEQ ID NO: 12.

8. An expression vector that encodes and stably expresses in vivo an antibody comprising (a) a light chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS: 45, 126 and 127 and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 7, 123 and 124.

9. An expression vector that encodes and stably expresses in vivo an antibody comprising (a) a light chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 41, 95, and 97 and (b) a heavy chain variable region comprising CDRs having the amino acid sequences of SEQ ID NOS: 6, 88 and 89.

10. The expression vector of any one of claims 6 - 9 wherein the expression vector comprises a viral based vector.

11. A pharmaceutical composition comprising the expression vector of any one of claims 6 - 9 .

12. A pharmaceutical composition comprising the expression vector of any one of claims 6 - 9 and a pharmaceutically acceptable carrier.

13. A method of inhibiting HIV in a host comprising administering to the host the expression vector as claimed in any one of claims 6 - 9 under conditions whereby the vector expresses the antibody.

14. A method of inhibiting HIV in a host comprising administering to the host the composition as claimed in claim 12 under conditions whereby the vector expresses the antibody.

Assignees

• Theraclone Sciences Inc
• Int Aids Vaccine Initiative
• Scripps Research Inst

Inventors

• Chan-Hui Po-Ying
• Frey Steven
• Olsen Ole
• Mitcham Jennifer
• Moyle Matthew
• Phogat Sanjay K
• Burton Dennis R
• Walker Laura Marjorie
• Poignard Pascal Raymond Georges
• Koff Wayne
• Simek-Lemos Melissa Danielle De Jean De St Marcel
• Kaminsky Stephen

Classifications

• A61P31/14

  for RNA viruses · CPC title

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K16/114 Primary

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title